FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase III Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

FibroGen, Inc. announced completion of patient enrollment for LELANTOS-2, a Phase III clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy.